top of page

NEWS

Jan 9, 2023

Amber Ophthalmics Announces Positive Topline Phase 2 Data Evaluating NEXAGON® For the Treatment of Persistent Corneal Epithelial Defect (PCED)

• Complete epithelial recovery was achieved by 67% of subjects receiving NEXAGON, as opposed to 27% receiving Vehicle alone
• NEXAGON was well-tolerated demonstrating a safety profile similar to vehicle
• Amber plans to initiate the NEXPEDE-1 Phase 2/3 clinical trial in subjects with PCED of various etiologies in Q1 2023

Read More
Amber Ophthalmics Announces Positive Topline Phase 2 Data Evaluating NEXAGON® For the Treatment of Persistent Corneal Epithelial Defect (PCED)

Dec 9, 2022

J.P. Morgan Health Care Conference 2023

Amber Ophthalmics to attend the J.P. Morgan Health Care Conference in San Francisco, CA

Read More
J.P. Morgan Health Care Conference 2023
bottom of page